R
Roberto Andini
Researcher at University of Naples Federico II
Publications - 48
Citations - 1525
Roberto Andini is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Colistin & Medicine. The author has an hindex of 14, co-authored 36 publications receiving 960 citations. Previous affiliations of Roberto Andini include Seconda Università degli Studi di Napoli.
Papers
More filters
Journal ArticleDOI
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul,Mical Paul,George L. Daikos,Emanuele Durante-Mangoni,Dafna Yahav,Dafna Yahav,Yehuda Carmeli,Yehuda Carmeli,Yael Dishon Benattar,Yael Dishon Benattar,Anna Skiada,Roberto Andini,Noa Eliakim-Raz,Noa Eliakim-Raz,Amir Nutman,Amir Nutman,Oren Zusman,Oren Zusman,Anastasia Antoniadou,Pia Clara Pafundi,Amos Adler,Yaakov Dickstein,Ioannis Pavleas,Rosa Zampino,Vered Daitch,Vered Daitch,Roni Bitterman,Hiba Zayyad,Fidi Koppel,Inbar Levi,Tanya Babich,Tanya Babich,Lena E. Friberg,Johan W. Mouton,Ursula Theuretzbacher,Leonard Leibovici,Leonard Leibovici +36 more
TL;DR: Combination therapy was not superior to monotherapy and the addition of meropenem to colistin did not improve clinical failure in severe A baumannii infections.
Journal ArticleDOI
Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
Emanuele Durante-Mangoni,Giuseppe Signoriello,Roberto Andini,Annunziata Mattei,Maria De Cristoforo,Patrizia Murino,Matteo Bassetti,Paolo Malacarne,Nicola Petrosillo,Nicola Galdieri,Paola Elvira Mocavero,Antonio Corcione,Claudio Viscoli,Raffaele Zarrilli,Ciro Gallo,Riccardo Utili +15 more
TL;DR: The results indicate that rifampicin should not be routinely combined with colistin in clinical practice, and that the increased rate of A. baumannii eradication with combination treatment could still imply a clinical benefit.
Journal ArticleDOI
Management of carbapenem-resistant Enterobacteriaceae infections
TL;DR: Observational studies and randomized clinical trials of CRE treatment are summarized, with a specific focus on the effects of monotherapy compared with combination treatment and a high risk of selection bias.
Journal ArticleDOI
Liver injury in remdesivir-treated COVID-19 patients.
Rosa Zampino,Ferruccio Mele,Letizia Lucia Florio,Lorenzo Bertolino,Roberto Andini,Maria Galdo,Rosanna De Rosa,Antonio Corcione,Emanuele Durante-Mangoni +8 more
TL;DR: In this paper, the authors describe liver toxicity in 5 COVID-19 patients treated with Remdesivir (RDV) in the intensive care unit (ICU) of Monaldi Hospital, Naples, Italy, during March and April 2020.
Journal ArticleDOI
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Yaakov Dickstein,Jonathan Lellouche,Ma’ayan Amar,David A. Schwartz,Amir Nutman,Vered Daitch,Dafna Yahav,Dafna Yahav,Leonard Leibovici,Anna Skiada,Anastasia Antoniadou,George L. Daikos,Roberto Andini,Rosa Zampino,Emanuele Durante-Mangoni,Johan W. Mouton,Lena E. Friberg,Yael Dishon Benattar,Yael Dishon Benattar,Roni Bitterman,Ami Neuberger,Yehuda Carmeli,Yehuda Carmeli,Mical Paul,Mical Paul,Hiba Zayyad,Fidi Koppel,Yael Zak-Doron,Sergey Altunin,Nizar Andria,Anat Stern,Neta Petersiel,Marina Raines,Amir Karban,Noa Eliakim-Raz,Oren Zusman,Michal Elbaz,Heyam Atamna,Tanya Babich,Amos Adler,Inbar Levi,Ioannis Pavleas,Antigoni Kotsaki,Domenico Iossa,Mariano Bernardo,Giusi Cavezza,Lorenzo Bertolino,Giuseppe Giuffre,Roberto Giurazza,Susanna Cuccurullo,Maria Galdo,Patrizia Murino,Adriano Cristinziano,Antonio Corcione,Pia Clara Pafundi,Johan Mouton,Anders N. Kristoffersson,Ursula Theuretzbacher +57 more
TL;DR: Colistin resistance as determined by BMD was associated with significantly lower mortality among patients with severe CRAB infections and colistin monotherapy wasassociated with a better outcome compared to colist in-meropenem combination therapy.